Long-term enzyme replacement therapy in Fabry patients protects against oxidative and inflammatory process
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-024-03499-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Alana Pimentel Moura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre (HCPA), Rua Ramiro Barcelos, Porto Alegre, RS, 235090035-903, Brazil. Hauptthemen laut MEDLINE: Fabry Disease, Oxidative Stress, Enzyme Replacement Therapy, alpha-Galactosidase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Abstract (Originalsprache)
Fabry disease (FD) is an X-linked recessive lysosomal storage disorder, characterized by a deficiency of α-galactosidase, which causes the progressive accumulation of glycosphingolipids, especially globotriaosylsphingosine (Gb3), in lysosomes across multiple organs. Substrate deposition, associated with tissue damage in FD, also contributes to the emergence of a pro-inflammatory state presented by some patients. We investigated pro- and anti-inflammatory cytokines, and the expression of inflammation-associated genes in treated FD patients, as well as oxidative parameters. We found a decrease in the production of cytokines IL-1β, IL-6, IL-10, and TNF-α in male FD patients and a normalization of redox status in male and female FD patients, once the levels of protein, lipid oxidation, and nitrite and nitrate content were like healthy individuals. Our results suggest that long-term ERT in men with FD contributes to the reduction of a pro-inflammatory scenario and a decrease of oxidative damage in patients, reflecting greater control throughout the disease and in the multisystemic changes characteristic of this disorder. These findings lead us to believe that long-term ERT can improve the redox status and protect these individuals against oxidative and nitrative stress, as well as the inflammatory process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre (HCPA), Rua Ramiro Barcelos, Porto Alegre, RS, 235090035-903, Brazil.
- Centro de Vacinas HCPA - Escritório de Projetos e Parcerias Estratégicas - HCPA, Porto Alegre, RS, Brazil.
- Programa de Pós-Graduação Em Ciências Farmacêuticas, Universidade Federal Do Rio Grande Do Sul (UFRGS), Porto Alegre, RS, Brazil.
- Programa de Pós-Graduação Em Ciências BiológicasBioquímica, Universidade Federal Do Rio Grande Do Sul (UFRGS), Porto Alegre, RS, Brazil.
- Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre (HCPA), Rua Ramiro Barcelos, Porto Alegre, RS, 235090035-903, Brazil. crvargas@hcpa.edu.br.
- Programa de Pós-Graduação Em Ciências Farmacêuticas, Universidade Federal Do Rio Grande Do Sul (UFRGS), Porto Alegre, RS, Brazil. crvargas@hcpa.edu.br.
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
Moura, A. P., Hammerschmidt, T. G., Guerreiro, G., Aguilar, C., Faverzani, J. L., Lopes, F. F., de Oliveira Poswar, F., Giugliani, R., Deon, M., & Vargas, C. R. (2025). Long-term enzyme replacement therapy in Fabry patients protects against oxidative and inflammatory process. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03499-5
Vancouver
Moura AP, Hammerschmidt TG, Guerreiro G, Aguilar C, Faverzani JL, Lopes FF, et al. Long-term enzyme replacement therapy in Fabry patients protects against oxidative and inflammatory process. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-024-03499-5
BibTeX
@article{Moura2025,
author = {Moura, Alana Pimentel and Hammerschmidt, Tatiane Grazieli and Guerreiro, Gilian and Aguilar, Camila and Faverzani, Jéssica Lamberty and Lopes, Franciele Fátima and de Oliveira Poswar, Fabiano and Giugliani, Roberto and Deon, Marion and Vargas, Carmen Regla},
title = {Long-term enzyme replacement therapy in Fabry patients protects against oxidative and inflammatory process},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-024-03499-5}
}
EUVIMED